Company Overview and News
MANILA, June 5 (Reuters) - Philippine fuel retailer Phoenix Petroleum said it had agreed to partner with a subsidiary of state-owned China National Offshore Oil Corp (CNOOC) to explore building a receiving terminal for liquefied natural gas in the country.
RDS.B RDS.A PSKXF FSGCY RDSB RDSA FSGCF FGENG FGENF FGEN RYDBF PHSXY PSE RYDAF
FIRST GEN Corp. is planning to invite diversified conglomerate San Miguel Corp. “within the year” to participate in its $1.2-billion liquefied natural gas (LNG) import facility, company officials said on Monday.
FSGCY SMCP1 SMGBY SMGBF FSGCF FGENG FGENF SMC2B SMC2A FGEN SMC SMC2D SMC2C SMC2F SMC2E
LOPEZ-LED First Philippine Holdings Corp. (FPH) is setting aside a budget of P22 billion for 2018, with its property development segment cornering the bulk of the capital expenditures, the company treasurer said on Monday.
FSGCF FGENG FGENF FGEN FSGCY FPH
SAN Miguel Corp. (SMC) said it is open to any form of tie-up with First Gen Corp. for the latter’s planned $1-billion liquefied natural gas (LNG) terminal.
FSGCY SMCP1 KEP SMGBY SMGBF FSGCF FGENG FGENF SMC2B SMC2A FGEN SMC SMC2D SMC2C SMC2F SMC2E
LOPEZ-LED First Gen Corp. expects its recurring net income in 2018 to reach nearly $200 million, an improvement over last year’s flat growth when two of its power plants were reporting losses.
FSGCF FGENG EGDCY FGENF MER FGEN FSGCY EDC 532219 ENERGYDEV
Lopez-led First Gen Corp. has set a firm schedule for its plan to build a liquefied natural gas (LNG) terminal and regasification facility, including the selection of a partner this year and the start of construction next year, company officials said.
FSGCF FGENG FGENF FGEN FSGCY LNG
LOCAL EQUITIES may continue to fall this week, as higher oil prices and faster inflation, among others, drag down investor sentiment.
EGDCY SMCP1 GTMEY 532219 RBLAY ENERGYDEV SMGBF FGENG FGENF SMC PHSXY GTMEF PSE GLOPA AYAAF PSKXF MWC FSGCY AYAAY GLOPP SMGBY FSGCF GLO SMC2B SMC2A FGEN SMC2D RLC SMC2C SMC2F SMC2E EDC ALI
Conglomerate Lopez Holdings posted a net profit of P4.22 billion last year, down by 36 percent in the absence of one-off gains and election season-related surge in media advertising revenue that jacked up its bottom line in 2016.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH
Conglomerate Lopez Holdings chalked up a net profit of P4.22 billion last year, down by 36 percent in the absence of one-off gains and election season-related surge in media advertising revenues that jacked up earnings in 2016.
FPHPC FSGCF FGENG FGENF FGEN FSGCY FPHP FPH
FIRST Philippine Holdings Corp. (FPH) reported on Friday a 15% increase in 2017 net profit on a recurring basis to P6.8 billion, which excludes a one-off item in connection with debt prepayments by unit First Gen Corp.
FPHPC EGDCY FSGCY 532219 FPHP ENERGYDEV FSGCF FGENG FGENF FGEN EDC FPH
FIRST GEN Corp. is aiming to secure power supply contracts for 92% of the capacity it generates this year, an improvement over the 80% it recorded last year, the Lopez-led company told the stock exchange.
FSGCF FGENG FGENF MER FGEN FSGCY
FIRST GEN Corp. is not giving up on its plan to build run-of-river hydroelectric power plants as the Lopez-led company is now “strengthening its expertise” in the construction and development of such facilities.
FSGCF FGENG FGENF FGEN FSGCY
FIRST Gen Corp. reported “flat earnings growth” for 2017, at $163 million, as the natural calamities that struck Leyte last year hit the performance of its geothermal and hydroelectric plants in the area.
FSGCF FGENG EGDCY FGENF FGEN FSGCY EDC 532219 ENERGYDEV
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET